NMN/NR and Diphenhydramine Interaction: What Clinicians and Patients Should Know

Why This Combination Raises Questions

NAD+ precursors like nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) have become two of the most widely used longevity supplements in the United States. Diphenhydramine, the active ingredient in Benadryl and dozens of OTC sleep aids, remains one of the most purchased over-the-counter medications. Patients frequently combine them without medical guidance, assuming that a supplement and an OTC antihistamine pose no risk together.

The Interaction Gap in Published Literature

No randomized controlled trial has studied this specific pair. The absence of data does not confirm safety. It means clinicians must reason from first principles: known pharmacokinetics, pharmacodynamic mechanisms, and the clinical profiles of each agent. That reasoning is what this article provides.

Why Clinicians Should Still Counsel Patients

Diphenhydramine is listed on the American Geriatrics Society (AGS) Beers Criteria as a medication to avoid in older adults due to its high anticholinergic burden and association with cognitive impairment [1]. Any co-administered agent that alters sleep architecture, circadian NAD+ cycling, or hepatic metabolism deserves a closer look when paired with a drug carrying that risk profile.

Pharmacokinetic Assessment: Metabolism and CYP Overlap

NMN and NR follow a primarily salvage-pathway metabolism rather than a classic hepatic CYP-mediated route. After oral intake, NMN is converted to NR in the gut (or taken directly as NR), absorbed into cells via equilibrative nucleoside transporters, and phosphorylated back to NMN inside the cell by nicotinamide riboside kinases (NRK1/NRK2) before conversion to NAD+ [2]. This pathway largely bypasses the cytochrome P450 system.

Diphenhydramine's CYP2D6 Inhibition

Diphenhydramine, by contrast, is extensively metabolized by CYP2D6, CYP1A2, and CYP2C9 [3]. It also acts as a moderate inhibitor of CYP2D6. This inhibition is clinically relevant for CYP2D6 substrates like codeine, metoprolol, and tamoxifen. NMN and NR are not CYP2D6 substrates, so diphenhydramine's inhibitory effect on this enzyme does not create a kinetic interaction with NAD+ precursors.

P-glycoprotein and Transporter Considerations

Diphenhydramine has been identified as a P-glycoprotein (P-gp) substrate and mild inhibitor [4]. NMN/NR cellular uptake depends on equilibrative nucleoside transporters (ENT1, ENT2), not P-gp. The transporter pathways do not overlap in a way that would change plasma levels of either compound.

Net Pharmacokinetic Risk

Based on divergent metabolic routes (salvage pathway vs. CYP-mediated oxidation) and non-overlapping transporter profiles, the pharmacokinetic interaction risk between NMN/NR and diphenhydramine is low.

Pharmacodynamic Assessment: Where the Real Conversation Begins

The more clinically interesting question is pharmacodynamic. Both compounds touch systems that regulate sleep, circadian rhythm, and neuronal function, though through different mechanisms.

NAD+ and Circadian Biology

NAD+ levels oscillate in a circadian pattern. The rate-limiting enzyme in NAD+ biosynthesis, NAMPT (nicotinamide phosphoribosyltransferase), is under direct transcriptional control of the CLOCK:BMAL1 complex [5]. Supplementing NMN or NR raises total NAD+ pools, which in turn activates sirtuins (SIRT1 and SIRT3 in particular). SIRT1 deacetylates BMAL1 and PER2, feeding back into clock gene regulation. A 2021 clinical trial (N=30) showed that 250 mg NMN taken in the afternoon improved lower-limb function and reduced drowsiness in older adults, suggesting a measurable effect on alertness and circadian-related physiology [6].

Diphenhydramine's CNS Depression

Diphenhydramine crosses the blood-brain barrier readily and blocks central H1 histamine receptors. This produces sedation, impairs psychomotor performance, and disrupts normal sleep architecture by suppressing REM sleep [7]. A 2000 study published in the Annals of Internal Medicine demonstrated that 50 mg diphenhydramine significantly impaired next-day cognitive and psychomotor function even in young, healthy adults [8].

The Opposing-Vector Concern

NMN/NR, through NAD+/sirtuin activation, tends to promote wakefulness-associated gene expression and mitochondrial activity. Diphenhydramine suppresses CNS alertness. These are opposing pharmacodynamic vectors. The clinical implication is not danger per se but rather suboptimal outcomes: taking NMN at bedtime alongside diphenhydramine could blunt the sleep-promoting effect of the antihistamine. Taking diphenhydramine in the morning alongside NMN could blunt the alertness-promoting effects of NAD+ repletion.

The timing-separation framework below resolves this opposition.

Recommended Timing and Dose Strategy

Proper scheduling eliminates most of the pharmacodynamic tension between these two agents. The goal is to align each compound with the phase of the circadian cycle it supports.

Morning NMN/NR, Evening Diphenhydramine

Take NMN or NR in the morning (before noon). This aligns NAD+ repletion with the natural peak of NAMPT expression in the first half of the day [5]. If diphenhydramine is being used as a sleep aid, take it 30 minutes before bedtime, consistent with the FDA-approved labeling for OTC diphenhydramine [9]. This creates a 10-to-14-hour separation window, far exceeding diphenhydramine's Tmax of 1 to 3 hours and allowing NMN's acute NAD+-boosting effects (peak at 2 to 3 hours post-dose) to occur during waking hours.

Dose Ranges in Current Evidence

Published human trials of NMN have used doses from 250 mg to 1,250 mg daily. The MIB-626 trial (N=32) tested 1,000 mg NMN twice daily and found it was well tolerated with dose-proportional increases in blood NAD+ metabolites [10]. NR has been studied at 100 mg to 2,000 mg/day, with the CHROMAVITA trial (N=140) confirming safety at 1,000 mg/day for 8 weeks [11]. Diphenhydramine OTC dosing is 25 to 50 mg for sleep; the FDA label recommends against exceeding 50 mg per dose.

No dose adjustment of either compound is required based on the other.

Anticholinergic Burden: The Diphenhydramine Side of the Equation

The real safety concern in this combination is not the interaction itself. It is the standalone anticholinergic burden of diphenhydramine, which deserves clinical scrutiny regardless of what else the patient takes.

Quantifying the Risk

Diphenhydramine scores a 3 (the maximum) on the Anticholinergic Cognitive Burden (ACB) scale [12]. A cumulative ACB score of 3 or higher is associated with increased risk of cognitive impairment, falls, and delirium. NMN and NR carry no anticholinergic activity, so they do not add to this burden. But they also do not mitigate it.

Older Adults Face Amplified Risk

The 2023 updated AGS Beers Criteria strongly recommends avoiding diphenhydramine in adults 65 and older [1]. For patients in this age group who are taking NMN/NR for longevity, the conversation should pivot from "is the interaction safe?" to "should diphenhydramine be replaced with a non-anticholinergic alternative?" Options include melatonin (0.5 to 3 mg), low-dose doxepin (3 to 6 mg, FDA-approved for insomnia), or cognitive behavioral therapy for insomnia (CBT-I), which the American College of Physicians recommends as first-line therapy [13].

When Diphenhydramine Is Appropriate

Short-term use (fewer than 2 weeks) for acute allergic symptoms or occasional insomnia in adults under 65, with no other anticholinergic medications on board, carries acceptable risk. In that scenario, co-administration with NMN/NR introduces no meaningful additional hazard beyond the timing considerations described above.

Monitoring Recommendations

No lab monitoring is required specifically for this combination. Clinical monitoring should focus on symptoms that reflect either pharmacodynamic opposition or anticholinergic accumulation.

What to Track

Watch for these signs during combined use:

• Sleep quality changes. If the patient reports that diphenhydramine "stopped working," ask about NMN/NR timing. Evening dosing of NAD+ precursors may counteract sedation.
• Morning grogginess. Residual diphenhydramine sedation (half-life 4 to 8 hours) may be perceived as worse if NMN-driven alertness is expected.
• Dry mouth, constipation, urinary retention. These are anticholinergic effects of diphenhydramine, not interaction effects, but they should be documented at each visit.
• Cognitive changes. Any new memory complaints or confusion in patients over 60 warrant a medication review and consideration of diphenhydramine discontinuation.

Duration-Based Reassessment

If a patient has been using diphenhydramine nightly for more than 14 days, reassess regardless of NMN/NR use. Chronic nightly diphenhydramine is associated with tolerance to the sedative effect within 3 to 7 days [14] and a higher risk of dementia with cumulative exposure per a 2015 JAMA Internal Medicine cohort study (N=3,434) [15].

Special Populations

Hepatic Impairment

Diphenhydramine undergoes extensive first-pass hepatic metabolism. Patients with moderate-to-severe liver disease (Child-Pugh B or C) may experience prolonged diphenhydramine half-life and increased sedation. NMN/NR metabolism through the salvage pathway is less dependent on hepatic function, but data in hepatically impaired patients is limited. Use lower diphenhydramine doses (25 mg) and monitor closely.

Renal Impairment

Both diphenhydramine metabolites and nicotinamide (the downstream metabolite of NMN/NR) are renally cleared. In patients with eGFR <30 mL/min/1.73 m², diphenhydramine clearance is reduced [9]. NMN supplementation in renal impairment has not been studied. Conservative dosing of both agents is appropriate.

Pregnancy and Lactation

Diphenhydramine is FDA Pregnancy Category B, with no controlled human data confirming safety [9]. NMN and NR lack any pregnancy safety data in humans. This combination should be avoided during pregnancy and lactation unless the antihistamine component is specifically directed by an obstetrician for acute allergic indications.

NAD+ Precursor Drug Interactions: The Broader Picture

While NMN and NR have a favorable interaction profile overall, patients taking these supplements should be aware of a few broader pharmacologic considerations.

Nicotinamide Accumulation

Both NMN and NR are ultimately converted to NAD+, which is broken down to nicotinamide. At high supplemental doses (above 1,000 mg/day of NMN or NR), nicotinamide levels may rise enough to inhibit sirtuins, paradoxically opposing the intended longevity effect [16]. This is not specific to diphenhydramine co-use, but it is relevant context for patients stacking multiple NAD+-boosting supplements.

Methylation Demand

Excess nicotinamide is cleared via methylation by nicotinamide N-methyltransferase (NNMT), consuming S-adenosylmethionine (SAMe) as a methyl donor [16]. Patients with MTHFR polymorphisms or marginal folate/B12 status could experience increased methylation stress at high NMN/NR doses. Again, this is independent of diphenhydramine, but clinicians evaluating the full supplement-plus-OTC picture should consider it.

Compounds That Do Interact With Diphenhydramine

Diphenhydramine has well-documented interactions with other CNS depressants (alcohol, benzodiazepines, opioids), MAO inhibitors, and other anticholinergic agents. These carry moderate-to-severe interaction ratings in standard DDI databases such as Lexicomp and Micromedex [3]. NMN/NR is not in this category.

Clinical Bottom Line

The NMN/NR plus diphenhydramine combination carries low pharmacokinetic interaction risk and a manageable pharmacodynamic profile. The primary clinical action is timing separation: NMN/NR in the morning, diphenhydramine at bedtime. For patients over 65, the stronger recommendation is to replace diphenhydramine with a non-anticholinergic sleep aid, a step supported by the AGS Beers Criteria [1] and the ACP insomnia guidelines [13] independent of NMN/NR use. Reassess any patient who has used diphenhydramine nightly for more than 14 consecutive days.